Evommune licenses Hinova autoimmune drug in deal
Evommune has licensed rights to Hinova Pharmaceuticals experimental autoimmune treatment in a deal worth up to 1.1 billion dollars. The California-based developer will pay 30 million upfront and plans a mid-stage study in 2027.
Xurve View
Insights:
Xurve View
Evommune licensed an experimental autoimmune drug from Hinova Pharmaceuticals in a licensing agreement valued at up to $1.1B in milestone payments. The deal grants the California-based drug developer global rights outside China for the oral treatment EVO570. The transaction expands Evommune's clinical pipeline into VAV1-targeted therapies for chronic inflammatory conditions.
